Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
DRUG

TNFi (Tumor Necrosis Factor inhibitor) medication

"Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly"

DRUG

Abatacept

"10 kg to \<25 kg 50 mg once weekly 25 kg to \<50 kg 87.5 mg once weekly~≥50 kg 125 mg once weekly"

DRUG

Tocilizumab

"\<30 kg 162 mg once every 3 weeks~≥30 kg 162 mg once every 2 weeks"

DRUG

Tofacitinib

"10 to \<20 kg 3.2 mg (3.2 mL oral solution) BID 20 to \<40 kg 4 mg (4 mL oral solution) BID~≥40 kg 5 mg (one 5 mg tablet or 5 mL oral solution) BID"

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Duke University

OTHER